Affiliation:
1. Universidade Federal do Rio de Janeiro, Instituto de Pesquisas de Produtos Naturais Walter Mors, Rio de Janeiro, Brazil
2. Universidade Federal do Rio de Janeiro, Instituto de Química, Rio de Janeiro, Brazil
Abstract
Abstract:
COVID-19, an airborne disease caused by a betacoronavirus named SARS--
CoV-2, was officially declared a pandemic in early 2020, resulting in more than 770 million
confirmed cases and over 6.9 million deaths by September 2023. Although the introduction
of vaccines in late 2020 helped reduce the number of deaths, the global effort to
fight COVID-19 is far from over. While significant progress has been made in a short period,
the fight against SARS-CoV-2/COVID-19 and other potential pandemic threats
continues. Like AIDS and hepatitis C epidemics, controlling the spread of COVID-19
will require the development of multiple drugs to weaken the virus's resistance to different
drug treatments. Therefore, it is essential to continue developing new drug candidates
derived from natural or synthetic small molecules. Coumarins are a promising
drug design and development scaffold due to their synthetic versatility and unique physicochemical
properties. Numerous examples reported in scientific literature, mainly by in
silico prospection, demonstrate their potential contribution to the rapid development of
drugs against SARS-CoV-2/COVID-19 and other emergent and reemergent viruses.
Publisher
Bentham Science Publishers Ltd.